Bristol-Myers Sues Alembic to Block Generic Versions of Sprycel

Bristol-Myers Squibb said Alembic’s proposed generic version of Sprycel infringes two patents for the blockbuster leukemia drug.

• Bristol-Myers is seeking court order blocking copies until patents have expired and cash compensation if copies are made before then, according to complaint filed Thursday in federal court in Newark, New Jersey
• Patents expire in August 2025 and September 2026: FDA Orange Book
• Bristol-Myers in July settled suits with Dr. Reddy’s and Lupin over three patents for Sprycel, including the two at issue in Alembic case
• Sprycel had U.S. sales of $600 million during the first six months of 2021, down ...